Transmembrane domain sequence requirements for activation of the p185(c- neu) receptor tyrosine kinase

Journal of Cell Biology

Volumn 137, Issue 3, 1997, Pages 619-631

  Chen, Lucinda I ^a   Webster, Melanie K ^a   Meyer, April N ^a   Donoghue, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CROUZON SYNDROME; DIMERIZATION; DWARFISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYDROGEN BOND; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; TANDEM REPEAT;

AMINO ACID SEQUENCE; CELL COMPARTMENTATION; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUTAMATES; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 0030969251     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.137.3.619     Document Type: Review

References (45)

1. Bargmann, C.I., and R.A. Weinberg. 1988a. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA. 85:5394-5398.
2. Bargmann, C.I., and R.A. Weinberg. 1988b. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. EMBO (Eur. Mol. Biol. Organ.) J. 7:2043-2052.
3. Bargmann, C.I., M.-C. Hung, and R.A. Weinberg. 1986a. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.). 319:226-230.
4. Bargmann, C.I., M.-C. Hung, and R.A. Weinberg. 1986b. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 45:649-657.
5. Beguinot, L., W.C. Vass, and M. Miloso. 1995. SHC is constitutively activated by a transforming EGF receptor mutant with a point mutation in the transmembrane domain. J. Cell Biochem. 19A(Suppl.):11-11.
6. Ben-Levy, R., E. Peles, R. Goldman-Michael, and Y. Yarden. 1992. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. J. Biol. Chem. 267:17304-17313.
7. Brown, V.I., N. Shah, R. Smith, M. Hellman, L. Jarett, Y. Mikami, E. Cohen, X. Qian, and M.I. Greene. 1994. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor. DNA Cell Biol. 13:193-209.
8. Burke, C.L., M.A. Lemmon, B.A. Coren, D.M. Engelman, and D.F. Stern. 1997. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene. 14:687-696.
9. neu* activation. EMBO (Eur. Mol. Biol. Organ.) J. 11:923-932.
10. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
11. Cosson, P., S.P. Lankford, J.S. Bonifacino, and R.D. Klausner. 1991. Membrane protein association by potential intramembrane charge pairs. Nature (Lond.). 351:414-416.
12. Dougall, W.C., X. Qian, and M.I. Greene. 1993. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J. Cell. Biochem. 53:61-73.
13. Dougall, W.D., X. Qian, N.C. Peterson, M.J. Miller, A. Samanta, and M.I. Greene. 1994. The neu-oncogene: signal transduction pathways, transformation mechanisms, and evolving therapies. Oncogene. 9:2109-2123.
14. Drebin, J.A., D.F. Stern, V.C. Link, R.A. Weinberg, and M.I. Greene. 1984. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature (Lond.). 312:545-548.
15. +-ATPase. J. Virol. 66:405-413.
16. Hannink, M., and D.J. Donoghue. 1986. Cell surface expression of membrane-anchored v-sis gene products: glycosylation is not required for cell surface transport. J. Cell Biol. 103:2311-2322.
17. Heldin, C.H. 1995. Dimerization of cell surface receptors in signal transduction. Cell. 80:213-223.
18. Horwitz, B.H., A.L. Burkhardt, R. Schlegel, and D. DiMaio. 1988. 44-amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids. Mol. Cell. Biol. 8:4071-4078.
19. Horwitz, B.H., D.L. Weinstat, and D. DiMaio. 1989. Transforming activity of a 16-amino-acid segment of the bovine papillomavirus E5 protein linked to random sequences of hydrophobic amino acids. J. Virol. 63:4515-4519.
20. Kashles, O., D. Szapary, F. Bellot, A. Ullrich, J. Schlessinger, and A. Schmid 1988. Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. Proc. Natl. Acad. Sci. USA. 8 9567-9571.
21. Lee, B.A., and D.J. Donoghue. 1992. Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction. J. Cell Biol. 118:1057-1070.
22. Lemmon, M.A., J.M. Flanagan, H.R. Treutlein, J. Zhang, and D.M. Engelman. 1992. Sequence specificity in the dimerization of transmembrane α-helices. Biochemistry. 31:12719-12725.
23. Maher, D.W., L.M. Strawn, and D.J. Donoghue. 1993. Alanine mutagenesis of conserved residues in the platelet-derived growth factor family: identification of residues necessary for dimerization and transformation. Oncogene. 8: 533-541.
24. Meyer, A.N., Y.-F. Xu, M.K. Webster, A.E. Smith, and D.J. Donoghue. 1994. Cellular transformation by a transmembrane peptide - structural requirements for the bovine papilloma virus E5 oncoprotein. Proc. Natl. Acad. Sci. USA. 91:4634-4638.
25. Meyers, G.A., S.J. Orlow, I.R. Munro, K.A. Przylepa, and E.W. Jabs. 1995. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat. Genet. 11:462-464.
26. Owens, R.J., C. Burke, and J.K. Rose. 1994. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. J. Virol. 68:570-574.
27. Peles, E., R.B. Levy, E. Or. A. Ullrich, and Y. Yarden. 1991. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ. EMBO (Eur. Mol. Biol. Organ.) J. 10:2077-2086.
28. Qian, X., W.C. Dougall, M.E. Hellman, and M.I. Greene. 1994. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene. 9:1507-1514.
29. Qian, X., W.C. Dougall, Z. Fei, and M.I. Greene. 1995. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene. 10:211-219.
30. Rousseau, F., J. Bonaventure, L. Legeai-Mallet. A. Pelet, J.-M. Rozet, P. Maroteaux, M. Le Merrer, and A. Munnich. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature (Lond.). 371: 252-254.
31. r tumour antigen. Nature (Lond.). 312:513-516.
32. Segatto, O., C.R. King, J.H. Pierce, P.P. Di Fiore, and S.A. Aaronson. 1988. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol. 8:5570-5574.
33. Shiang, R., L.M. Thompson, Y.-Z. Zhu, D.M. Church, T.J. Feilder, M. Bocian, S.T. Winokur, and J.J. Wasmuth. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78:335-342.
34. Shin, C., L.C. Padhy, M. Murray, and R.A. Weinberg. 1981. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (Lond.). 290:261-264.
35. Siegel, P.M., D.L. Dankort, W.R. Hardy, and W.J. Muller. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068-7077.
36. Stein, D., J. Wu, S.A.W. Fuqua, C. Roonprapunt, V. Yajnik, P. D'Eustachio, J.J. Moskow, A.M. Buchberg, C.K. Osborne, and B. Margolis. 1994. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO (Eur. Mol. Biol. Organ.) J. 13: 1331-1340.
37. neu stimulates tyrosine phosphorylation in vivo. Mol. Cell. Biol. 8:3969-3973.
38. Sternberg, M.J.E., and W.J. Gullick. 1989. Neu receptor dimerization. Nature (Lond.). 339:587.
39. Sternberg, M.J.E., and W.J. Gullick. 1990. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng. 3:245-248.
40. Treutlein, H.R., M.A. Lemmon, D.M. Engelman, and A.T. Brunger. 1992. The glycophorin A transmembrane domain dimer: sequence-specific propensity for a right-handed supercoil of helices. Biochemistry. 31:12726-12733.
41. Ullrich, A., and J. Schlessinger. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:203-212.
42. Webster, M.K., and D.J. Donoghue. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO (Eur. Mol. Biol. Organ.) J. 15:520-527.
43. Weiner, D.B., Y. Kokai, T. Wada, J.A. Cohen, W.V. Williams, and M.I. Greene. 1989a. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene. 4:1175-1183.
44. Weiner, D.B., J. Liu, J.A. Cohen, W.V. Williams, and M.I. Greene. 1989b. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (Lond.). 339:230-231.
45. Wides, R.J., N.B. Zak, and B.-Z. Shilo. 1990. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain. Eur. J. Biochem. 189:637-645.